Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Balkees Abderrahman' s stories

Sort by: Newest first Oldest first A-Z Z-A

  • Chemoprevention in British women is inadequate Subscription

    31 MAR 2017 11:12 By Balkees Abderrahman, V. Craig Jordan

    We write to outline our concerns that breast cancer prevention strategies are not being implemented to their fullest potential in the UK.

  • Breast cancer prevention trumps cure Subscription

    23 DEC 2016 11:44 By Balkees Abderrahman, V. Craig Jordan

    Breast cancer is the most prevalent female cancer and is estimated to increase by 50% by 2030 compared to the incidence in 2011. The decision by the National Institute for Health and Care Excellence (NICE), the UK health technology appraiser, to recommend the use of preventive medicines, which are known to decrease the risk of developing breast cancer, is a welcome advance in public health.

  • Illustration of breast cancer and hormone replacement therapy (HRT)

    Assessing the safety of hormonal replacement therapy Subscription

    8 NOV 2016 17:03 By Balkees Abderrahman, V. Craig Jordan

    Since the dawn of hormonal replacement therapy — now known as menopausal hormone therapy — there have been conflicting reports about its risks and safety. A thorough examination of the evidence suggests it can be used safely in menopausal women.

  • 3D MRI scan of a breast with breast cancer

    Improving long-term adjuvant anti-oestrogenic therapy for breast cancer Subscription

    8 JUN 2016 13:38 By Balkees Abderrahman, V. Craig Jordan

    Long-term (five years) adjuvant tamoxifen treatment for oestrogen receptor-positive, or ER-positive, breast cancer post-surgery is recognised as a major advance in healthcare. Clinical trials comparing standard and extended tamoxifen therapy found a major decrease in mortality occurred in the ten years following a decade of adjuvant therapy. Studies in premenopausal breast cancer patients showed that ovarian function suppression (OFS) plus an aromatase inhibitor (AI), ...

Show  10 per page20 per page

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.